- ►nih.gov - Free from Publisher J Garcia-Arumi, A Boixadera, J Giralt, V … - British Journal of Ophthalmology, 2005 - bjo.bmj.com Results: Benzyl alcohol concentration was decreased significantly in all the
techniques used compared with the original commercial suspension (p<0.05), with
no significant differences among them. The reduction was approximately one ... Cited by 45 - Related articles - BL Direct - All 9 versions
MC Hernaez-Ortega, E Soto-Pedre - Ophthalmic surgery, lasers & imaging: the official … - ncbi.nlm.nih.gov Purification of triamcinolone acetonide suspension is important to avoid the
potential toxic effects of the vehicle. The aim of this article is to describe a
simple and rapid technique to remove the vehicle, instead of the long ... Cited by 36 - Related articles - BL Direct - All 3 versions
VL MORRISON, HJ KOH, L Cheng, K … - Retina, 2006 - journals.lww.com Methods: Nine New Zealand rabbits were injected with either a control or a test
article at elevating concentrations. The test article was benzyl alcohol
calculated to give final injected concentrations of 0.0073%, 0.022%, ... Cited by 74 - Related articles - BL Direct - All 5 versions
A Nishimura, A Kobayashi, Y Segawa, M … - Retina, 2003 - journals.lww.com Purpose: To report a new, simple, rapid method to isolate triamcinolone
acetonide particles and to remove additives from its commercially available
suspension (Kenacort-A) for intravitreal use. Methods: The contents of a ... Cited by 51 - Related articles - BL Direct - All 2 versions
UHM Spandau, M Derse, P Schmitz-Valckenberg … - American journal of ophthalmology, 2005 - Elsevier In recent studies, triamcinolone acetonide has been intravitreally injected as
treatment for intraocular edematous and neovascular diseases. [1] , [2] , [3]
and [4] In these studies, triamcinolone acetonide was used either ... Cited by 15 - Related articles - All 13 versions
H Rodriguez-Coleman, P Yuan, H Kim, L … - Archives of Ophthalmology, 2004 - archopht.highwire.org We read with great interest the recent article by Jonas et al 1 in the January
2003 issue of the ARCHIVES. Because of the authors' statement that eyes can
tolerate intravitreal triamcinolone acetonide doses of 25 mg, we decided to ... Cited by 33 - Related articles - BL Direct - All 4 versions
W Kai, J Yanrong, L Xiaoxin - Graefe's Archive for Clinical and Experimental …, 2006 - Springer Abstract Background: Intravitreal triamcinolone acetonide (TA) has been widely
used as a therapeutic method for many ocular diseases, but a consensus on an
appropriate safe therapeutic window of dosage for intravitreal injection, ... Cited by 22 - Related articles - BL Direct - All 2 versions
AC Westfall, A Osborn, D Kuhl, MS Benz, WF … - Archives of Ophthalmology, 2005 - Am Med Assoc You are seeing this message because your Web browser does not support basic Web
standards. Find out more about why this message is appearing and what you can do
to make your experience on this site better. ... Objective To report the ... Cited by 47 - Related articles - All 4 versions
- ►nih.gov - Free from Publisher UHM Spandau, M Derse, P Schmitz- … - British Journal of Ophthalmology, 2005 - bjo.bmj.com Methods: The prospective, randomised, double masked, clinical interventional
study included 27 eyes (27 patients) with diffuse diabetic macular oedema. They
were randomly divided into three study groups receiving an intravitreal ... Cited by 59 - Related articles - BL Direct - All 10 versions
- ►nih.gov S Shaikh, S Ho, LA Engelmann, SW Klemann - British Journal of Ophthalmology, 2006 - bjo.bmj.com Triamcinolone acetonide (9α-fluoro-16α-hydroxyprednisolone) is a synthetic
crystalline corticosteroid with potent anti-inflammatory properties. Various
trade formulations are approved for the therapy of inflammatory conditions ... Cited by 18 - Related articles - BL Direct - All 9 versions
